# Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

> **NCT05976893** · PHASE4 · UNKNOWN · sponsor: **Xiang Xie** · enrollment: 620 (estimated)

## Conditions studied

- ASCVD
- Atherosclerotic Cardiovascular Disease
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- Cancer

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Statin

## Key facts

- **NCT ID:** NCT05976893
- **Lead sponsor:** Xiang Xie
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 620 (ESTIMATED)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05976893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05976893, "Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05976893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*